K Ciechanowski
Overview
Explore the profile of K Ciechanowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
262
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stepniewska J, Dolegowska B, Golembiewska E, Marchelek-Mysliwiec M, Domanski M, Ciechanowski K, et al.
J Physiol Pharmacol
. 2020 Aug;
71(2).
PMID: 32776910
The complement cascade is a part of innate immune system that responds rapidly to defend the host against invading microorganisms and complete the action of immune cells. The activation of...
2.
Marchelek-Mysliwiec M, Dziedziejko V, Nowosiad-Magda M, Wisniewska M, Safranow K, Pawlik A, et al.
Physiol Res
. 2019 Oct;
68(6):947-954.
PMID: 31647290
Chronic kidney disease adversely affects the structure and metabolism of bone tissue, which may be a result of disturbed biochemical processes in adipose tissue. Renal replacement therapy is a life-saving...
3.
Pabisiak K, Krejczy A, Bohatyrewicz R, Ciechanowski K
Transplant Proc
. 2018 Sep;
50(7):1953-1956.
PMID: 30177086
Background: Healthcare staff working in emergency medical services (EMS) and hospital emergency departments serve a key role in identifying potential donors after cardiac death in Maastricht category II. Methods: An...
4.
Pabisiak K, Ostrowski M, Kram A, Safranow K, Slojewski M, Ciechanowski K
Transplant Proc
. 2016 Oct;
48(7):2450-2453.
PMID: 27742319
Background: Due to demographic projections, and lack of an algorithm in the case of a prostate specific antigen (PSA)-positive donor, the loss of organ recovery may occur more frequently in...
5.
Kloda K, Domanski L, Kwiatkowska E, Safranow K, Drozd A, Ciechanowicz A, et al.
Transplant Proc
. 2016 Aug;
48(5):1451-5.
PMID: 27496426
Background: Reports regarding recipient's nonmodifiable genetic factors affecting telomerase activity and thus allograft function are lacking. Therefore the aim of this study was to analyze the associations between recipients' rs2735940...
6.
Pabisiak K, Ostrowski M, Kram A, Safranow K, Myslak M, Sienko J, et al.
Transplant Proc
. 2016 Aug;
48(5):1374-7.
PMID: 27496408
Currently, there is no clear position regarding the donation of organs from donors with prostate carcinoma (CaP) in European countries, except Italy. The lengthening of life expectancy increases the probability...
7.
Kabat-Koperska J, Kolasa-Wolosiuk A, Wojciuk B, Wojciechowska-Koszko I, Roszkowska P, Krasnodebska-Szponder B, et al.
Scand J Immunol
. 2016 Mar;
83(6):418-26.
PMID: 27007325
This experimental study assessed the impact of medications frequently used after kidney transplantation on the immune system of pregnant female Wistar rats. The study evaluates medications, both approved and contraindicated...
8.
Romanowski M, Domanski L, Pawlik A, Osekowska B, Dziedziejko V, Safranow K, et al.
Eur Rev Med Pharmacol Sci
. 2015 Sep;
19(17):3152-6.
PMID: 26400516
Objective: Post-transplant diabetes mellitus (PTDM) is a common complication after organ transplantation which leads to impaired graft function. Various factors may increase the risk of the development of PTDM. It...
9.
Nowosiad-Magda M, Myslak M, Roszkowska P, Borowiec-Chlopek Z, Urasinska E, Rozanski J, et al.
Transplant Proc
. 2014 Nov;
46(8):2606-12.
PMID: 25380877
Background: Anti-human leukocyte antigens antibodies (HLA) are not always the main cause of graft injury but can be a marker of immune response to the graft. The aim of this...
10.
Budde K, Bunnapradist S, Grinyo J, Ciechanowski K, Denny J, Silva H, et al.
Am J Transplant
. 2014 Oct;
14(12):2796-806.
PMID: 25278376
This Phase III randomized trial examined efficacy and safety of a novel once-daily extended-release tacrolimus formulation (LCP-Tacro [LCPT]) versus twice-daily tacrolimus in de novo kidney transplantation. Primary efficacy end point...